On April 19th, the "Forum on Internationalization of TCM Regulation and Achievement Transformation," hosted by the University of Macau and organized by Aishikang (Shanghai) Health Consulting Co., Ltd., successfully concluded. As a professional force deeply involved in the commercialization and industrialization of biopharmaceuticals, Xinghan Biotechnology was honored to be invited to attend. Mr. Liu Weimin, Vice President of the company, was invited to attend and serve as a guest speaker in a roundtable dialogue, and participated with many entrepreneur partners to jointly explore effective paths for going global.

This forum focused on two core directions: "Internationalization of TCM Regulation" and "Transformation of University Achievements." It brought together regulatory government representatives, top universities, research institutes, and industry representatives from mainland China, Hong Kong, Macao, as well as Singapore, Indonesia, and other regions. The event aims to explore feasible paths for Macao as a gateway for international cooperation in Traditional Chinese Medicine, promote deep integration of industry, academia, and research in TCM, and facilitate the landing of innovative achievements, thereby helping the TCM industry to go global with high quality.

During the forum, several roundtable dialogues were held on topics such as international cooperation, capital matchmaking, and cultural reshaping. The specially set up "Industry-Academia-Research Implementation" session witnessed the signing ceremony of the University of Macau's Innovation and Entrepreneurship Center and the roadshows of four excellent startup projects, providing a practical matchmaking platform for scientific research achievements to move from the laboratory to industrialization.

In the second roundtable discussion, "Unblocking the Innovation Chain: Capital Dialogue and Transformation Breakthroughs in TCM Industry-Academia-Research," Mr. Liu Weimin, Vice President of Xinghan Biotechnology, as an industry representative, engaged in dialogue with academic, investment, and research experts from the University of Macau, Hengqin Research Institute, Ransheng Industrial, Fujian Capital, and Reheart Institute.

刘为敏先生围绕“生物科技资本如何助力中医药早期研发与产业化落地”“产学研合作中的风险与机遇评估”等关键议题，分享了星瀚的产业实践与思考。他指出，在中医药现代化与国际化的浪潮中，专业生物科技企业扮演着连接前沿科研成果与规模化市场应用的“关键桥梁”角色。有效的资本介入不应仅限于资金支持，更需深度理解科研规律、参与转化路径设计、整合产业链资源，从而实现从实验室到病床旁的价值闭环。

此次高规格国际论坛为星瀚生物科技提供了与全球监管机构、学术带头人及投资伙伴深度交流的宝贵机会。衷心感谢主办方的精心组织与邀请，让产业声音得以在政策与学术交汇的平台上充分表达。

Through this event, Xinghan not only showcased its professional insights in biopharmaceutical investment and industrialization to the industry, but also established extensive connections with potential partners from multiple countries and regions. In the future, Xinghan will continue to uphold the philosophy of "Connecting Science, Empowering Health," deeply participate in the modernization and internationalization of Traditional Chinese Medicine, actively empower the transformation of cutting-edge scientific research achievements, and work hand in hand with partners from all walks of life to jointly promote the innovative development of the big health industry.